SCOTLAND has become the first part of the UK to make a new treatment for women with advanced cervical cancer available on the NHS.
The Scottish Medicines Consortium (SMC) has approved the use of the drug pembrolizumab – which is also known as Keytruda – to treat those patients with persistent or recurrent cervical cancer, or in cases where the disease has spread.
Campaigners have hailed the decision as giving “new options, hope and most importantly time to those living with advanced cervical cancer”.
READ MORE: Fergus Ewing 'doing Alister Jack's bidding' in DRS row, Greens say
Approval was granted after the drug was considered as part of the SMC’s Patient and Clinician Engagement (Pace) process, which is used for medicines designed to treat rare conditions or help patients at the end of their life.
Manufacturers MSD welcomed the decision, saying it would “help patients to spend more time with their loved ones”.
Stuart Robertson, head of devolved nations at MSD UK, said: “Advanced cervical cancer is an incurable disease, associated with significant morbidity, which is a painful diagnosis for patients.
“There are more diagnoses of advanced cervical cancer in areas of high deprivation and amongst people of working age.
“Until now there have been limited treatment options for these patients, creating a high unmet need.
“MSD is delighted that the Scottish Medicines Consortium will now enable patients in Scotland to access a new treatment option and, most importantly, may help patients to spend more time with their loved ones.”
Around 3200 cases of cervical cancer are diagnosed each year in the UK, with the disease leading to the deaths of about 800 women a year.
Campaigners at Jo’s Cervical Cancer Trust welcomed the decision, with chief executive Samantha Dixon saying: “Those diagnosed with advanced cervical cancer have few options when it comes to treatment.
“It is a much-overlooked area and so we are delighted that pembrolizumab has been approved for use in Scotland.
READ MORE: Chinese spy balloons may have 'already flown over UK airspace'
“It will give new options, hope and most importantly time to those living with advanced cervical cancer.
“Too frequently we hear from women having to fight for access to new treatments, with their options affected by where they live and sadly sometimes their wealth.
“We hope to see other UK nations follow and end the postcode lottery of care for advanced cervical cancer.”
Pembrolizumab is currently used across the UK to treat other forms of cancer, with a decision expected soon from the National Institute for Health and Care Excellence (Nice) on whether its use can be extended to cervical cancer patients in England.
The drug was one of two new cancer treatments approved by the SMC, with the green light also given for nivolumab – also known as Optivo – which is used to treat patients with a form of bladder cancer.
It too was accepted for use on the NHS after being considered through the Pace process.
Meanwhile, the SMC has agreed to make a new treatment available for the next three years for adults with the rare genetic condition X-linked hypophosphataemia.
This can cause bone fractures, early osteoarthritis, dental problems and an increased risk of osteoporosis in sufferers, with the drug burosumab – which is also known as Crysvita – being approved as part of a process for new treatments for extremely rare conditions.
As it has a “very high” cost it will be available for the next three years, allowing the SMC to obtain “greater clarity” about its benefits.
Speaking about the decisions, SMC chairman Mark MacGregor said: “We are pleased to be able to accept pembrolizumab for the treatment of cervical cancer and nivolumab for bladder cancer.
READ MORE: Two-thirds of Scots reject 'de facto referendum' on independence
“The committee is aware that delaying progression of the disease for as long as possible is very valuable to patients and families.”
He added: “Adults will now gain access to burosumab while the company gathers additional evidence to inform a decision in three years.
“X-linked hypophosphataemia is a chronic and severely debilitating condition that causes pain and fatigue and is life-limiting for patients.
“The costs of burosumab are very high relative to the identified benefits and this additional time will give the company the opportunity to provide greater certainty around the benefits for patients.”
Why are you making commenting on The National only available to subscribers?
We know there are thousands of National readers who want to debate, argue and go back and forth in the comments section of our stories. We’ve got the most informed readers in Scotland, asking each other the big questions about the future of our country.
Unfortunately, though, these important debates are being spoiled by a vocal minority of trolls who aren’t really interested in the issues, try to derail the conversations, register under fake names, and post vile abuse.
So that’s why we’ve decided to make the ability to comment only available to our paying subscribers. That way, all the trolls who post abuse on our website will have to pay if they want to join the debate – and risk a permanent ban from the account that they subscribe with.
The conversation will go back to what it should be about – people who care passionately about the issues, but disagree constructively on what we should do about them. Let’s get that debate started!
Callum Baird, Editor of The National
Comments: Our rules
We want our comments to be a lively and valuable part of our community - a place where readers can debate and engage with the most important local issues. The ability to comment on our stories is a privilege, not a right, however, and that privilege may be withdrawn if it is abused or misused.
Please report any comments that break our rules.
Read the rules hereLast Updated:
Report this comment Cancel